Biotech News
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
investors.designtx.com2026-05-06 14:59 EST
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Patients Underway Phase 2 Biomarker